Immune targets such as PD-L1, PD-1, and CTLA-4 have been shown to be effective in a variety of tumors, and targeting immune cells to activate checkpoints has been shown to be the most effective way to activate anti-tumor immune responses (Rotte, 2019). The gene discussed is CTLA4; the disease is neoplasm.